Overview

Update
IPO / Stock
Went Public on May 6, 2015 / NASDAQ:ADAP
Total Equity Funding
$104M in 1 Round from 12 Investors
Headquarters:
Oxton, York
Description:
Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.
Founders:
Categories:
Biopharma, Health Care, Biotechnology, Medical
Website:
http://adaptimmune.com
Social:

Company Details

Update
Founded:
2008
Contact:
| (440) 123-5430
Employees:
51 - 100 | 5 in Crunchbase

Adaptimmune Limited develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases. It utilizes the T cell to target and destroy cancerous or infected cells by using affinity T cell receptor proteins as a means of strengthening patient T cell responses. The company was incorporated in 2007 and is based in Abingdon, United Kingdom.

Funding Rounds (3) - $149.5M

Update
DateAmount / RoundValuationLead InvestorInvestors
Apr, 2017$42M / Post Ipo Equity0
Sep, 2014$104M / Series A12
Mar, 2014$3.5M / Grant1

Current Team (5)

Update

Offices/Locations (2)

Update
  • Headquarters

    University City Science Center

    3711 Market Street, 8th Floor

    Philadelphia, Pennsylvania 19104

    United States

  • Headquarters

    91 Park Drive,Milton Park

    Abingdon

    Oxton, York 14 4RY

    United Kingdom

Images (1)

Update

Add Acquisitions

Add Board Members and Advisors

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos